ADC Therapeutics (ADCT) to Release Quarterly Earnings on Monday

ADC Therapeutics (NYSE:ADCT) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Monday, May 5th. Analysts expect the company to announce earnings of ($0.38) per share and revenue of $17.71 million for the quarter.

ADC Therapeutics (NYSE:ADCT) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.06. The business had revenue of $19.00 million for the quarter, compared to analyst estimates of $19.01 million. On average, analysts expect ADC Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

ADC Therapeutics Stock Performance

Shares of ADCT opened at $1.45 on Friday. The stock has a 50 day simple moving average of $1.47 and a 200 day simple moving average of $1.93. ADC Therapeutics has a 52-week low of $1.05 and a 52-week high of $5.17. The firm has a market capitalization of $143.31 million, a PE ratio of -0.60 and a beta of 1.55.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on ADCT shares. HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of ADC Therapeutics in a research report on Monday, March 31st. Guggenheim lowered their target price on ADC Therapeutics from $10.00 to $7.00 and set a “buy” rating for the company in a report on Monday, March 31st. Stephens boosted their price target on ADC Therapeutics from $6.00 to $8.00 and gave the company an “overweight” rating in a report on Monday, February 24th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ADC Therapeutics in a research report on Friday, March 7th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $7.75.

About ADC Therapeutics

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.